Biovica's DiviTum(R) TKa Results Presented at SABCS

Author's Avatar
Nov 22, 2022

UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B, Financial) (FRA:9II, Financial) Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world's largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum® TKa to predict the efficacy of CDK4/6 inhibitors in metastatic breast cancer.